United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells t...
1040 Spring Street
Silver Spring, MD 20910
Founded in 1996
Katherine J. Klein Joins the United Therapeutics Corporation Board of Directors
Nov 13 14
United Therapeutics Corporation announced the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014. Professor Klein has served as the Vice Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management since 2005.
United Therapeutics Corporation Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014
Oct 28 14
United Therapeutics Corporation announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $329,950 million, operating loss of $32,236 million, loss before income taxes of $35,833 million, net loss of $25,237 million or $0.53 per diluted share compared to the total revenues of $302,225 million, operating income of $104,649 million, income before income taxes of $101,179 million, net income of $62,685 million or $1.17 per diluted share for the same quarter a year ago.
For the nine months period, the company reported total revenues of $942,156 million, operating income of $360,223 million, income before income taxes of $350,416 million, net income of $224,139 million or $4.12 per diluted share compared to the total revenues of $827,967 million, operating income of $320,990 million, income before income taxes of $310,533 million, net income of $204,874 million or $3.9 per diluted share for the same period a year ago.
United Therapeutics Corporation to Report Q3, 2014 Results on Oct 28, 2014
Oct 21 14
United Therapeutics Corporation announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Oct 28, 2014